Idevax (2021)

In March 2013, Novosanis was founded in collaboration with the University of Antwerp (VAXINFECTIO and Product Development; formerly Artesis University College) and Voxdale (Design & Engineering company), under the leadership of Vanessa Vankerckhoven (CEO) and Koen Beyers (CTO). Novosanis was funded by Taste Invest.
Novosanis was sold to Orasure Technologies in 2019 and when Idevax was founded earlier this year , VAX-ID® one of the devices developed by Novosanis was bought back by Idevax.
VAX-ID®, the heart of the Idevax company, is an award-winning patented drug delivery device suited for intradermal injection.
The device can be preconfigured with a 32G needle as well as with a 27G needle to allow for different applications, with a penetration depth of 0.85 and 1.2mm respectively.
The device is suited for accurate drug delivery of therapeutic, prophylactic and allergy drugs and vaccines in the dermal layer of the skin. In light of the COVID pandemic, intradermal injection can offer a solution due to its dose-sparing potential. Studies using influenza and Hepatitis B vaccines have shown that only one fifth up to one tenth of the dose is needed to achieve a non-inferior immune response compared to the full dose administered intramuscularly or subcutaneously.